These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 34621669)
1. Identification of Gender-Specific Molecular Differences in Glioblastoma (GBM) and Low-Grade Glioma (LGG) by the Analysis of Large Transcriptomic and Epigenomic Datasets. Khan MT; Prajapati B; Lakhina S; Sharma M; Prajapati S; Chosdol K; Sinha S Front Oncol; 2021; 11():699594. PubMed ID: 34621669 [TBL] [Abstract][Full Text] [Related]
2. Analysis of the EGFR Amplification and CDKN2A Deletion Regulated Transcriptomic Signatures Reveals the Prognostic Significance of Wang H; Wang X; Xu L; Zhang J; Cao H Front Oncol; 2021; 11():551160. PubMed ID: 33959491 [No Abstract] [Full Text] [Related]
3. Identification of potential biomarkers related to glioma survival by gene expression profile analysis. Hsu JB; Chang TH; Lee GA; Lee TY; Chen CY BMC Med Genomics; 2019 Mar; 11(Suppl 7):34. PubMed ID: 30894197 [TBL] [Abstract][Full Text] [Related]
4. Comprehensive Transcriptomic Analysis and Experimental Validation Identify lncRNA HOXA-AS2/miR-184/COL6A2 as the Critical ceRNA Regulation Involved in Low-Grade Glioma Recurrence. Chen PY; Li XD; Ma WN; Li H; Li MM; Yang XY; Li SY Onco Targets Ther; 2020; 13():4999-5016. PubMed ID: 32581558 [TBL] [Abstract][Full Text] [Related]
5. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data. Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666 [TBL] [Abstract][Full Text] [Related]
6. Low expression of CDHR1 is an independent unfavorable prognostic factor in glioma. Wang H; Wang X; Xu L; Lin Y; Zhang J; Cao H J Cancer; 2021; 12(17):5193-5205. PubMed ID: 34335936 [No Abstract] [Full Text] [Related]
7. Comprehensive Bioinformatics Analysis of mRNA Expression Profiles and Identification of a miRNA-mRNA Network Associated with the Pathogenesis of Low-Grade Gliomas. Wang M; Cui Y; Cai Y; Jiang Y; Peng Y Cancer Manag Res; 2021; 13():5135-5147. PubMed ID: 34234557 [TBL] [Abstract][Full Text] [Related]
8. Identification of tumor-associated antigens and immune subtypes of lower-grade glioma and glioblastoma for mRNA vaccine development. Wang ZL; Huang RY; Han B; Wu F; Sun ZY; Li GZ; Zhang W; Zhao Z; Liu X Chin Neurosurg J; 2022 Oct; 8(1):34. PubMed ID: 36307882 [TBL] [Abstract][Full Text] [Related]
9. GliomaDB: A Web Server for Integrating Glioma Omics Data and Interactive Analysis. Yang Y; Sui Y; Xie B; Qu H; Fang X Genomics Proteomics Bioinformatics; 2019 Aug; 17(4):465-471. PubMed ID: 31811943 [TBL] [Abstract][Full Text] [Related]
10. Identification of Core Genes and Screening of Potential Targets in Glioblastoma Multiforme by Integrated Bioinformatic Analysis. Yang J; Yang Q Front Oncol; 2020; 10():615976. PubMed ID: 33718116 [TBL] [Abstract][Full Text] [Related]
11. Differential expression of the circadian clock network correlates with tumour progression in gliomas. Petkovic M; Yalçin M; Heese O; Relógio A BMC Med Genomics; 2023 Jul; 16(1):154. PubMed ID: 37400829 [TBL] [Abstract][Full Text] [Related]
12. Identification of an autophagy-related 10-lncRNA-mRNA signature for distinguishing glioblastoma multiforme from lower‑grade glioma and prognosis prediction. Wei B; Wang L; Zhao J Gen Physiol Biophys; 2021 Jul; 40(4):257-274. PubMed ID: 34350832 [TBL] [Abstract][Full Text] [Related]
13. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas. Paul Y; Mondal B; Patil V; Somasundaram K Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842 [TBL] [Abstract][Full Text] [Related]
14. Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma. Cheng W; Li M; Jiang Y; Zhang C; Cai J; Wang K; Wu A J Neurosurg; 2016 Jul; 125(1):7-16. PubMed ID: 26544773 [TBL] [Abstract][Full Text] [Related]
15. Integrating multiple-level molecular data to infer the distinctions between glioblastoma and lower-grade glioma. Zhang X; Lu X; Liu Z; Guan R; Wang J; Kong X; Chen L; Bo C; Tian K; Xu S; Bai M; Zhang H; Li J; Wang L; Shen J; Guo M Int J Cancer; 2019 Aug; 145(4):952-961. PubMed ID: 30694558 [TBL] [Abstract][Full Text] [Related]
16. Integrated Analysis of the Clinical and Molecular Characteristics of IDH Wild-Type Gliomas in the Chinese Glioma Genome Atlas. Wang P; Liu Y; Zhi L; Qiu X Front Oncol; 2021; 11():696214. PubMed ID: 34307160 [TBL] [Abstract][Full Text] [Related]
17. A Computational Framework to Identify Biomarkers for Glioma Recurrence and Potential Drugs Targeting Them. Ma S; Guo Z; Wang B; Yang M; Yuan X; Ji B; Wu Y; Chen S Front Genet; 2021; 12():832627. PubMed ID: 35116059 [No Abstract] [Full Text] [Related]
18. Identification of Gender- and Subtype-Specific Gene Expression Associated with Patient Survival in Low-Grade and Anaplastic Glioma in Connection with Steroid Signaling. Hirtz A; Lebourdais N; Thomassin M; Rech F; Dumond H; Dubois-Pot-Schneider H Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077653 [TBL] [Abstract][Full Text] [Related]
19. Analysis of Gene Co-Expression Network to Identify the Role of CD8 + T Cell Infiltration-Related Biomarkers in High-Grade Glioma. Feng P; Li Y; Tian Z; Qian Y; Miao X; Zhang Y Int J Gen Med; 2022; 15():1879-1890. PubMed ID: 35228815 [TBL] [Abstract][Full Text] [Related]
20. A comprehensive analysis of the angiogenesis-related genes in glioblastoma multiforme vs. brain lower grade glioma. Biterge-Sut B Arq Neuropsiquiatr; 2020 Jan; 78(1):34-38. PubMed ID: 32074192 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]